{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/105857895"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "For example, metabotropic glutamate receptor ligands should be useful in the treatment of diseases or conditions including epilepsy, cerebral ischemia, pain, anxiety, spinal cord injury, chronic neurodegenerative diseases (e.g. Alzheimer's disease), Lou Gherig's disease (ALS), Parkinson's disease, Multiple Sclerosis and other diseases or conditions that result in progressive loss of neuronal cells" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "google.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/318770496"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/105857895" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/436841063"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/105857895" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/352471493"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/105857895" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/26769944"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/105857895"] } } }
